I think we’re living in a really exciting time. You know, all the advances that we’re seeing, both in the tracer design and imaging modalities, but also imaging analysis techniques and radiomics and like how we can, you know, use and employ AI to make our understanding and interpretation better. Ultimately, with the goal of using these tools to tailor our treatments for patients, you know, like that is just that future that we’re all looking for, striving for is that idea that a personalized approach to your treatment, that it’s no one size fits all...
I think we’re living in a really exciting time. You know, all the advances that we’re seeing, both in the tracer design and imaging modalities, but also imaging analysis techniques and radiomics and like how we can, you know, use and employ AI to make our understanding and interpretation better. Ultimately, with the goal of using these tools to tailor our treatments for patients, you know, like that is just that future that we’re all looking for, striving for is that idea that a personalized approach to your treatment, that it’s no one size fits all. It’s, you know, I think that this study is an example of, you know, we’ve shown one dose does great things, but some patients need one dose. Some people need the higher dose ipilimumab. Some people need only need the PD-1 nanotherapy, and some people can go to surgery alone and you know, and that’s um we don’t know how to tell those people apart at the moment and I’m really hopeful that these novel imaging modalities like CD8 PET will be a tool in doing that. I don’t think it’s going to be a single silver bullet I think that what we’re moving towards is you know multiple modalities at once helping us inform um how we plan and guide our treatment decisions both before treatment and while on treatment tailoring them. I think CD8 PET offers a really exciting way of imaging the immune system. Again, that benefit of the serial capacity to monitor something non-invasively over the course of treatment. I think it has applications in advanced melanoma, such as TIL therapy, picking harvest sites. And we have lots of ways you could employ it across melanoma and many other cancers. So I think that it’s really valuable. That’s proof of concept. And this that we are identifying the CD8 cells. But, you know, I think now it’s about how do we make it clinically actionable? And I think that’s the next step. And I would draw people’s attention to. There is a poster being presented on Monday in the developmental therapeutics where CD8 PET similarly were analyzed by a radiomics signature. and they did see an association in advanced melanoma with a certain modeled signature with response to therapy. And I think that really, you know, our study, we only look at SUV max, mean, peak and CD8 tumor volume. And there’s just so much more in these images that we should and could be analyzing and we’re going to. So I think I’m really excited about what it holds, but not quite there yet. But I think coming soon. Thank you.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
